SEC Form 4 · accession 0001470831-26-000745
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maricel Apuli
Officer — Chief Accounting Officer
Period of report
Jul 30, 2026
Accepted (ET)
Aug 3, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 30, 2026 | S | 2,000 | $80.06 | D | 127,401 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.